Haemonetics (NYSE:HAE) vs. Nevro (NYSE:NVRO) Head to Head Review

Haemonetics (NYSE:HAE) and Nevro (NYSE:NVRO) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Analyst Ratings

This is a breakdown of recent recommendations for Haemonetics and Nevro, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Haemonetics 0 0 5 0 3.00
Nevro 2 3 6 0 2.36

Haemonetics presently has a consensus target price of $144.40, indicating a potential upside of 11.56%. Nevro has a consensus target price of $65.73, indicating a potential downside of 26.90%. Given Haemonetics’ stronger consensus rating and higher possible upside, research analysts clearly believe Haemonetics is more favorable than Nevro.

Risk and Volatility

Haemonetics has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Nevro has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.

Profitability

This table compares Haemonetics and Nevro’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Haemonetics 5.05% 21.07% 10.91%
Nevro -24.51% -41.07% -20.43%

Insider and Institutional Ownership

99.0% of Haemonetics shares are held by institutional investors. 1.3% of Haemonetics shares are held by insiders. Comparatively, 7.6% of Nevro shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Haemonetics and Nevro’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Haemonetics $967.58 million 6.79 $55.02 million $2.39 54.16
Nevro $387.29 million 7.17 -$49.21 million ($1.64) -54.82

Haemonetics has higher revenue and earnings than Nevro. Nevro is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

Summary

Haemonetics beats Nevro on 11 of the 14 factors compared between the two stocks.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. The company also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx and El-Dorado Donor donation and blood unit management systems; Hemasphere software that provides support for blood drive planning; and Donor Doc and e-Donor software to enhance the donor recruitment and retention. In addition, it offers hospital products comprising TEG diagnostic systems that enables clinicians to assess the coagulation status of a patient at the point-of-care or laboratory setting; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; Cell Saver Elite +, a surgical blood salvage system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; OrthoPAT, a perioperative autotranfusion system for orthopedic procedures; and BloodTrack, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. Haemonetics Corporation was founded in 1971 and is headquartered in Braintree, Massachusetts.

About Nevro

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its solution for chronic pain also includes HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. The company sells its products through its direct sales force, and a network of sales agents and independent distributors. Nevro Corp. was founded in 2006 and is headquartered in Redwood City, California.

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.